CFO
ATNM icon

Callan Family Office’s Actinium Pharmaceuticals ATNM Stock Holding History

Callan Family Office’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,944
Closed -$11.9K – 1227
2026
Q1 		$11.9K Sell
11,944
-11,659
-49% -$13.9K ﹤0.01% 1130
2025
Q4 		$32.1K Hold
23,603
– – ﹤0.01% 1101
2025
Q3 		$37.8K Hold
23,603
– – ﹤0.01% 837
2025
Q2 		$33K Hold
23,603
– – ﹤0.01% 904
2025
Q1 		$38K Buy
+23,603
New +$30K ﹤0.01% 541

Other funds holding ATNM

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CFM
Compass Financial Management Tampa, Florida $829M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Callan Family Office's ATNM Position: Q2 2026 in Review

Callan Family Office sold out of Actinium Pharmaceuticals (ATNM) in Q2 2026, closing a stake of 11,944 shares — an estimated $11.9K sold.

Callan Family Office first reported a position in ATNM in Q1 2025 and held it in 5 quarters. The position peaked at $38K in Q1 2025. 47 funds tracked by Wall St. Rank hold ATNM as of Q2 2026.

  • Callan Family Office reported no remaining Actinium Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Callan Family Office sold 11,944 Actinium Pharmaceuticals shares in Q2 2026, an estimated $11.9K.
  • Callan Family Office first reported a position in Actinium Pharmaceuticals in Q1 2025 and held it in 5 quarters.
  • Callan Family Office's Actinium Pharmaceuticals position peaked at $38K in Q1 2025.
  • 47 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.